Reviewing Curative Biotechnology (OTCMKTS:CUBTD) and Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) and Curative Biotechnology (OTCMKTS:CUBTD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Earnings & Valuation

This table compares Veracyte and Curative Biotechnology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$561.90 million	6.08	$66.35 million	$1.41	30.16
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A

Veracyte has higher revenue and earnings than Curative Biotechnology.

Analyst Ratings

This is a summary of recent ratings and target prices for Veracyte and Curative Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	2	6	2	2.82
Curative Biotechnology	0	0	0	0	0.00

Veracyte presently has a consensus price target of $54.33, indicating a potential upside of 27.75%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than Curative Biotechnology.

Profitability

This table compares Veracyte and Curative Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Curative Biotechnology	N/A	N/A	N/A

Volatility & Risk

Veracyte has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Summary

Veracyte beats Curative Biotechnology on 9 of the 9 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.